COMMUNIQUÉS West-GlobeNewswire

AMN Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026
09/04/2026
DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook on Thursday, May [...]
Weight Watchers Announces Board Committee Appointments
09/04/2026
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced the following updates to the [...]
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
09/04/2026
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m [...]
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
09/04/2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
09/04/2026
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat [...]
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
09/04/2026
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s third major pharma [...]
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
09/04/2026
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, [...]
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
09/04/2026
Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and explainable AI for trial design in psychedelic clinical development. TORONTO, April 09, 2026 (GLOBE [...]
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
09/04/2026
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a [...]
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
09/04/2026
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S [...]
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
09/04/2026
JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro [...]
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
09/04/2026
Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support the high end of [...]
Soleo Health Opens New Ambulatory Infusion Center in Austin, Texas
09/04/2026
FRISCO, Texas and AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the opening of its new ambulatory [...]
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
09/04/2026
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for [...]
Valitor to Participate in the 25th Annual Needham Virtual Healthcare Conference
09/04/2026
BERKELEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory D. Kunst will share a [...]
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
09/04/2026
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive DIFS [...]
Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
09/04/2026
Results from the first-ever randomized control trial for the REGENETEN Implant in partial - thickness rotator cuff repair Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces [...]
Seres Therapeutics to Present at CARB-X Investor Day
09/04/2026
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X [...]
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
09/04/2026
Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline [...]

Pages